Recent

% | $
Quotes you view appear here for quick access.

ConocoPhillips Message Board

e7navy1999 140 posts  |  Last Activity: Feb 8, 2016 9:39 PM Member since: Jan 21, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    ONVO - Cash 76.86M ---- NO DEBT

    by asianmarket37 Dec 8, 2015 2:05 PM
    e7navy1999 e7navy1999 Dec 8, 2015 2:10 PM Flag

    I suggest you listen to the podcast. Our CEO clearly explains the cash situation and the need to focus on wise use of cash.

    Sentiment: Strong Buy

  • e7navy1999 e7navy1999 Dec 9, 2015 10:12 AM Flag

    Many of us longs are not concerned with the day to day ups/downs. We are here for the long haul...the day when human livers and kidneys can be printed and transplanted...the day when new drugs are developed based on the 3D assay testing. Long haul. We are mostly "investors" in the technology....not traders

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 25, 2015 1:38 PM Flag

    Looks like ONVO got a head start in this Bull Santa Claus Rally!

    Sentiment: Strong Buy

  • Go ONVO. Go Queensland Research! Go Dr Little

    Sentiment: Strong Buy

  • Reply to

    Cashmoo finally admits ONVO was a mistake

    by sa134551 Dec 15, 2015 8:37 AM
    e7navy1999 e7navy1999 Dec 15, 2015 4:42 PM Flag

    I just added sa...means "sad #$%$" to my block list

    Sentiment: Strong Buy

  • Reply to

    Kidney validation

    by cashmoo2 Nov 9, 2015 4:13 PM
    e7navy1999 e7navy1999 Dec 19, 2015 12:42 PM Flag

    Alex...this is one of ONVO's exclusive partners

    Sentiment: Strong Buy

  • Reply to

    UPS needs to eliminate it's dividend.

    by msch8864 Jan 15, 2016 9:54 AM
    e7navy1999 e7navy1999 Jan 26, 2016 5:33 PM Flag

    When one gets my ripe old age the dividend is all that matters. Most of us old geezer s don't care about the principle. It is income security and stability

  • Reply to

    Serious quesion for my fellow longs,

    by aga0115 Jan 21, 2016 2:20 PM
    e7navy1999 e7navy1999 Jan 21, 2016 3:18 PM Flag

    Onvo could show significant income from the cosmetics partnership...in that case...to the moon we go. Might show more partnerships, might show surprising kidney progress? anything can happen. Might just be needing more time to mature. What ever the case...don't be surprised if the stock shoots up 3000% in a milli-second on good news

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Nov 16, 2015 1:02 PM Flag

    “On a combined corporate basis, focusing on our balance sheet, our assets increased 12% year to date to $749,000,000 and owners equity increased 13% to $109,000,000. Correspondingly, that means our return on equity for the 9 month period is also 13%. We have a book value per share of $8.34 which compares very favorably to our current stock price which is in the low $6.00 range."

    Sentiment: Strong Buy

  • Reply to

    Book Value $8.34

    by e7navy1999 Nov 16, 2015 1:02 PM
    e7navy1999 e7navy1999 Nov 16, 2015 2:08 PM Flag

    exactly, they should consider just buying all outstanding shares from us and make her private. I doubt they really care since they are all millionaires anyway. They just keep doing business the way it has always been. They do not seem too interested in holding investor concerns and value in mind

    Sentiment: Strong Buy

  • e7navy1999 e7navy1999 Dec 7, 2015 10:10 AM Flag

    I got my finger on the trigger to buy more. Perfect timing the end of the month Nov i did not buy yet

    Sentiment: Strong Buy

  • Reply to

    I too wrote a letter to Steve

    by cashmoo2 Dec 16, 2015 11:15 AM
    e7navy1999 e7navy1999 Dec 16, 2015 2:40 PM Flag

    me2

    Sentiment: Strong Buy

  • awesome article on HART and a link to ONVO Harvard research

    Sentiment: Strong Buy

  • Reply to

    wheres the bottom?

    by jayeluk1983 Dec 29, 2015 2:37 PM
    e7navy1999 e7navy1999 Dec 29, 2015 8:48 PM Flag

    all this is a buying opportunity. No one thought Amazon was going to soar like it did. When ONVO pops I would be in the double digit millions. All on spare change...$2.50 ish is chump change and a bargain for an MIT CEO working for us prosperous longs.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Dec 4, 2015 9:22 AM Flag

    Market Cap $86 million, Revenue $276 million, cash on hand $97 million, book Value $8.34. Actual todays share price ......22% below book value!!!!!...not to mention the 5% stock dividend to be announce later this month. Come on management...(CEO to be specific) lets at least push to meet book value. Clear out some of the dead weight and bring in some fresh ideas.

  • Reply to

    Sharon Presnell

    by cashmoo2 Jan 12, 2016 9:05 PM
    e7navy1999 e7navy1999 Jan 13, 2016 8:46 AM Flag

    good catch moo. 10hrs before official release! awesomesauce

    Sentiment: Strong Buy

  • Reply to

    On Organovo's Twitter Page:

    by twojugglers Dec 20, 2015 12:45 PM
    e7navy1999 e7navy1999 Dec 21, 2015 11:28 AM Flag

    Just in case the newbees do not know who Sharon is: Dr. Presnell has more than 18 years of experience in the leadership of product-focused R&D. As an assistant professor at the University of North Carolina at Chapel Hill, Dr. Presnell’s research in liver and prostate biology and carcinogenesis produced cell- and tissue-based technologies that were outlicensed for industrial applications. She joined Becton Dickinson (BD) in 2001 and played a key role in the early discovery and development of BD’s Discovery Platform and FACSTM CAP tools for the optimization of in vitro culture environments and flow cytometry-based characterization of cells. In her role at BD, she grew and led a large multi-disciplinary team to establish feasibility for the Discovery Platform and FACS CAP in multiple therapeutic areas, including diabetes, and stewarded both technologies through revenue-generating commercial partnerships. Dr. Presnell joined Tengion, Inc. in 2007 as the Vice President of Regenerative Medicine Research, and was responsible for the discovery and early development of Tengion’s Neo-Kidney Augment™ technology, which MedTronic secured first rights to purchase in a 2011 deal. Dr. Presnell holds a Ph.D. in pathology from the Medical College of Virginia.

    Sentiment: Strong Buy

  • e7navy1999 by e7navy1999 Dec 8, 2015 9:53 AM Flag

    I wonder if the jump in PPS a few minutes ago was from me buying more at such a bargain basement price. One just has to trust the management and trust the technology. Japan lingering in the backdrop was my main motive for buying more this week

    Sentiment: Strong Buy

  • e7navy1999 e7navy1999 Dec 7, 2015 8:54 AM Flag

    Kirk Malloy, Ph.D.

    Dr. Malloy has held management and executive leadership positions in rapidly growing life science and diagnostics companies for 18 years. He is currently Senior Vice President and General Manager of Life Sciences at Illumina, a leading developer and supplier of genetic analysis instrumentation, assays and software for the life science and diagnostics markets. At Illumina, Dr. Malloy oversees the company’s core platform technologies and the core life sciences markets they enable. He joined Illumina in 2002 and has served as Vice President of Customer Solutions and Vice President of Quality, building and leading the commercial support organization and a robust service business for all of Illumina’s markets. Prior to joining Illumina, Dr. Malloy built and managed training, support and validation services at Biosite Inc., a leading provider of rapid diagnostics products, where he helped build the point of care cardiovascular diagnostics test market. Dr. Malloy earned his B.S. in biology from the University of Miami and his M.S. and Ph.D. from the University of Delaware and held post-doctoral positions at Boston University and Northeastern University. He completed a certification for Corporate Directors at UCLA Anderson School of Management.

    Sentiment: Strong Buy

  • e7navy1999 e7navy1999 Dec 7, 2015 8:58 AM Flag

    Robert Baltera, Jr., M.S., M.B.A.

    Mr. Baltera is the CEO of Laguna Pharmaceuticals. A seasoned pharmaceutical industry executive, Mr. Baltera acquired a wealth of business and product management experience during 17 years with biotech pioneer Amgen. In his recent role as CEO of Amira Pharmaceuticals, he led the company to acquisition by Bristol-Meyers Squibb Company. He was instrumental in focusing Amira’s development efforts, strengthening and developing its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Before becoming Amira’s CEO, Mr. Baltera held a number of senior management positions at Amgen, the last being vice president of corporate and contract manufacturing. He successfully used his collective experience to serve as team leader responsible for the approval of Kineret™ in rheumatoid arthritis, a highlight of his many accomplishments while at Amgen. Mr. Baltera also serves in senior roles in several organizations, as Executive Chairman of Synovex, on the Board of Directors of Panmira Pharmaceuticals, on the Board of Directors of San Diego Venture Group, and on the Board of Trustees of the Keck Graduate Institute. He has an M.B.A. from the Anderson School at UCLA and earned his B.S. in microbiology and a M.S. in genetics from The Pennsylvania State University.

    Sentiment: Strong Buy

COP
32.09-1.24(-3.69%)Feb 10 4:00 PMEST